Alpha 2.0
Login Register
» Articles » PMID: 8033429

The Use of Intravenous Immune Globulin in Multiple Myeloma

Overview
Journal Clin Exp Immunol
Publisher Oxford University Press
Specialty Allergy & Immunology
Date 1994 Jul 1
PMID 8033429
Citations 7
Authors
H M Chapel
M Lee
Affiliations
Soon will be listed here.
Abstract

Patients with multiple myeloma suffer from serious bacterial infections throughout the course of the disease. This is probably associated with reduced polyclonal immunoglobulin synthesis. Prophylactic intravenous immune globulin (IVIG) reduces the incidence and recurrence of these infections in the stable phase of the disease. Infections at times of induction chemotherapy and/or relapse have a wider range of causative organisms. Such susceptibility may be associated with abnormal phagocytic function following chemotherapy.

Citing Articles

Variation in immunoglobulin use and impact on survival in myeloma.

Chai K, Wellard C, Thao L, Aoki N, Moore E, Augustson B EJHaem. 2024; 5(4):690-697.

PMID: 39157592 PMC: 11327709. DOI: 10.1002/jha2.938.

IgG replacement in multiple myeloma.

Wonnaparhown A, Hilal T, Squire J, Freeman C, Fonseca R Blood Cancer J. 2024; 14(1):124.

PMID: 39054331 PMC: 11272770. DOI: 10.1038/s41408-024-01107-6.

A Case of Multiple Myeloma Presenting as Meningitis with Fungemia.

Noginskiy I, Samra A, Nielsen K, Kalavar M Case Rep Oncol. 2018; 11(3):705-710.

PMID: 30483102 PMC: 6243956. DOI: 10.1159/000493852.

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

Atanackovic D, Luetkens T, Kroger N Leukemia. 2013; 28(5):993-1000.

PMID: 24153012 DOI: 10.1038/leu.2013.310.

Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.

Karlsson J, Andreasson B, Kondori N, Erman E, Riesbeck K, Hogevik H Clin Vaccine Immunol. 2011; 18(6):969-77.

PMID: 21508164 PMC: 3122605. DOI: 10.1128/CVI.00021-11.

References
1.
TWOMEY J . Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med. 1973; 132(4):562-5. View
2.
Durie B, Salmon S . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(3):842-54. DOI: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. View
3.
Perri R, Hebbel R, Oken M . Influence of treatment and response status on infection risk in multiple myeloma. Am J Med. 1981; 71(6):935-40. DOI: 10.1016/0002-9343(81)90303-x. View
4.
Fahey J, SCOGGINS R, UTZ J, SZWED C . INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA. Am J Med. 1963; 35:698-707. DOI: 10.1016/0002-9343(63)90140-2. View
5.
Schifferli J, LESKI M, Favre H, Imbach P, Nydegger U, Davies K . High-dose intravenous IgG treatment and renal function. Lancet. 1991; 337(8739):457-8. DOI: 10.1016/0140-6736(91)93395-p. View